Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

 

Reality Check on Anemia — Chronic Kidney Disease

Market access for anemia treatments due to chronic kidney disease reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In November 2019, AstraZeneca said its FibroGen-partnered drug roxadustat, an oral first-in-class drug to treat anemia in patients with chronic kidney disease, demonstrated positive results in its Phase III trial
  • Key Findings: Contracting is common for preferred status, and patients may have to try and fail a preferred product first

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.

MMIT-RC_Thumbnail_1-1.png